An FDA advisory panel will be voting on whether or not Purdue Pharma's abuse-deterrent formulation (ADF) of oxycodone (OxyContin) "meaningfully reduced" opioid-related overdoses and deaths since it was introduced in the market 10 years ago.
A change needed in dealing with mental illness in the U.S. amidst the COVID-19 pandemic
Prior to COVID-19 the U.S. was in the midst of a mental illness crisis. Then with COVID-19, situation worsened even more. According to the poll conducted by American Psychiatric Association, one third of Americans said the coronavirus had a serious impact on their mental health.
Mental health related insurance claims in the U.S. have risen
Mental health-related insurance claims in the United States have risen by 108% between 2007 to 2017, according to the new independent analysis from FAIR Health.
President Donald Trump signs opioid bill into law and vows to end the ‘scourge’ of drug addiction
President Donald Trump signed the bill known as the SUPPORT for Patients and Communities Act, to improve the country’s opioid epidemic response efforts.